Show simple item record

dc.contributor.authorKessler, Uteen_US
dc.contributor.authorSchøyen, Helle Kristineen_US
dc.contributor.authorAndreassen, Ole Andreasen_US
dc.contributor.authorEide, Geir Egilen_US
dc.contributor.authorHammar, Åsaen_US
dc.contributor.authorMalt, Ulrik Fredriken_US
dc.contributor.authorØdegaard, Ketil Joachimen_US
dc.contributor.authorMorken, Gunnaren_US
dc.contributor.authorSundet, Kjetil Sørenen_US
dc.contributor.authorVaaler, Arne Einaren_US
dc.date.accessioned2015-12-16T13:43:16Z
dc.date.available2015-12-16T13:43:16Z
dc.date.issued2013-04-04
dc.PublishedBMC Psychiatry 2013, 13eng
dc.identifier.issn1471-244X
dc.identifier.urihttps://hdl.handle.net/1956/10760
dc.description.abstractBackground The literature on the neuropsychological profiles in Bipolar disorder (BD) depression is sparse. The aims of the study were to assess the neurocognitive profiles in treatment-resistant, acutely admitted BD depression inpatients, to compare the neurocognitive functioning in patients with BD I and II, and to identify the demographic and clinical illness characteristics associated with cognitive functioning. Methods Acutely admitted BD I (n = 19) and BD II (n = 32) inpatients who fulfilled the DSM-IV-TR criteria for a major depressive episode were tested with the MATRICS Consensus Cognitive Battery (MCCB), the Wechsler Abbreviated Scale of Intelligence, the National Adult Reading Test, and a battery of clinical measures. Results Neurocognitive impairments were evident in the BD I and BD II depression inpatients within all MCCB domains. The numerical scores on all MCCB-measures were lower in the BD I group than in the BD II group, with a significant difference on one of the measures, category fluency. 68.4% of the BD I patients had clinically significant impairment (>1.5 SD below normal mean) in two or more domains compared to 37.5% of the BD II patients (p = 0.045). A significant reduction in IQ from the premorbid to the current level was seen in BD I but not BD II patients. Higher age was associated with greater neurocognitive deficits compared to age-adjusted published norms. Conclusions A high proportion of patients with therapy-resistant BD I or II depression exhibited global neurocognitive impairments with clinically significant severity. The cognitive impairments were more common in BD I compared to BD II patients, particularly processing speed. These findings suggest that clinicians should be aware of the severe neurocognitive dysfunction in treatment-resistant bipolar depression, particularly in BD I.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.0eng
dc.subjectBipolar disorder depressioneng
dc.subjectBipolar II disordereng
dc.titleNeurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depressionen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2015-09-11T13:15:59Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright Kessler et al.; licensee BioMed Central Ltd.
dc.identifier.doihttps://doi.org/10.1186/1471-244x-13-105
dc.identifier.cristin1023736
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Psykiatri, barnepsykiatri: 757
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Psychiatry, child psychiatry: 757
dc.subject.nsiVDP::Medisinske Fag: 700en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY